Email Updates

You are here

HIV Vaccine

An HIV vaccine is imperative for an enduring end to the epidemic.

An effective preventive HIV vaccine would teach the body how to prevent HIV infection. Vaccines are the most powerful public health tool—and an HIV vaccine would play an essential role in ensuring the end to the AIDS epidemic.

While effective vaccines remain years away, there are more reasons for hope than ever before. HIV vaccine research is more productive than ever, with multiple large-scale vaccine trials underway and dozens of vaccine approaches in development.

What We're Reading

Johnson & Johnson and partners announced that the Imbokodo study, a large-scale HIV vaccine proof-of-concept trial also known as HVTN 705/ HPX2008, did not significantly reduce the overall risk of HIV acquisition among over 2,600 women in five sub-Saharan African countries. The Adenovirus26-based mosaic vaccine regimen was shown to be safe, but it did not meet pre-defined criteria for efficacy to warrant moving forward for longer follow-up. A companion study, the Phase III Mosaico trial, will continue.

August 31, 2021

Johnson & Johnson, together with a consortium of global partners, announced results from the primary analysis of a Phase 2b HIV vaccine clinical trial known as the Imbokodo study (also known as HVTN 705/HPX2008). Data showed the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV.

August 31, 2021
Johnson & Johnson

An advanced HIV vaccine trial in Africa has been shut down after data showed the shots offered only limited protection against the virus, researchers announced on Tuesday. The vaccine, made by Johnson & Johnson, is one in a long line found to offer little defense against HIV, one of medicine’s most intractable adversaries.

August 31, 2021
New York Times
Subscribe to RSS - HIV Vaccine